How many nivolumab doses are typical in a cycle?

Nivolumab is a medication used to treat various types of cancer, including melanoma, non-small cell lung cancer, and renal cell carcinoma. It works by blocking the PD-1 protein on T-cells, allowing them to attack cancer cells more effectively [1].

According to clinical guidelines and product information, a typical dose of nivolumab for adult patients is 240 mg administered intravenously over 30 minutes every 2 weeks [2]. A standard treatment cycle for nivolumab consists of four doses given over a 16-week period, followed by a rest period. The exact number of doses in a cycle can vary depending on the specific treatment protocol and clinical context.

For example, a clinical trial for nivolumab in patients with melanoma or non-small cell lung cancer used a dosing schedule of nivolumab 240 mg every 2 weeks for 4 cycles (8 doses) followed by 12 weeks of rest [3]. However, not all patients may receive the full 8 doses of nivolumab in a cycle, and some may receive fewer doses due to adverse events or disease progression.

For more information on nivolumab dosing and treatment regimens, please refer to the product information and clinical guidelines available on websites like DrugPatentWatch.com [4].

Sources:

[1] https://www.drugs.com/monograph/nivolumab-oral.html
[2] https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125514s000lbl.pdf
[3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4306610/
[4] https://www.drugpatentwatch.com/DrugPatentWatch/drug.php?drug=1339